New FDA Plan Accused of Being a Tool for Political Intervention, Drug Approvals May Be Influenced by Senior Officials

The U.S. Food and Drug Administration (FDA) has launched a new program to expedite drug reviews by issuing "Commissioner's Priority Review" credentials, which is rapidly evolving into a tool used by the White House and senior FDA political officials to influence which drugs are approved for market as quickly as possible. Historically, the FDA has sought to entrust drug approval processes to professional scientists to avoid political interference, even avoiding the appearance of political intervention. However, now senior FDA officials have become deeply involved in all aspects of this new program. At least once, they ignored staff concerns and still granted the relevant credentials to certain drugs. Furthermore, as part of the White House's push for drug pricing agreements, senior FDA officials have also pressured staff to issue such credentials to certain companies.

Image source: Internet

Original article: toutiao.com/article/1852002232942603/

Statement: This article represents the views of the author.